急性髓系白血病克隆演化与微小残留病的检测  

The clone evolution and minimal residual disease detection in acute myeloid leukemia

作　　者：李蔚[1] 邱林[1] Li Wei;Qiu Lin(Institute of Hematology and Oncology,First Hospital of Harbin,Harbin 150010,China)

机构地区：[1]哈尔滨市第一医院哈尔滨血液病肿瘤研究所,哈尔滨150010

出　　处：《中华转移性肿瘤杂志》2022年第1期83-87,共5页Chinese Journal of Metastatic Cancer

摘　　要：急性髓系白血病(AML)是具有高度异质性的血液系统恶性肿瘤,其表现为髓系肿瘤细胞在外周血、骨髓、髓外组织的克隆性扩增,导致患者贫血、出血、发热,直至死亡。微小残留病(MRD)是检测AML肿瘤负荷最有效的手段,常用的方法包括多参数流式细胞术和RT-PCR。但二代高通量测序(NGS)技术更适合检测AML患者克隆演化过程,因为其可以同时检测高通量的突变基因。本文就AML克隆演化及NGS检测AML的MRD的最新进展做一综述。Acute myeloid leukemia(AML)is a highly heterogeneous hematologic malignancy,showing clonogenic expansion of myeloid tumor cells in peripheral blood,bone marrow,extrtramulla tissue,leading to anemia and bleeding and fever until death.Minor residual disease(MRD)is the most effective means of detecting AML tumor load,and common methods include multi-parametric flow cytometry and RT-PCR.But thenext-generation sequencing(NGS)technology is better suited to detect the clonal evolution of AML patients,because it can simultaneously detect high-throughput mutant genes.This paper summarizes the recent progress on the clonal evolution of AML and the MRD detection of AML by NGS.

关 键 词：急性髓系白血病 微小残留病 二代高通量测序检测 

分 类 号：R733.71[医药卫生—肿瘤]